Novavax


Back in the early days of COVID-19 vaccine development, three strategies were being pursued: recombinant adenovirus (AstraZenica and J&J), mRNA (Moderna and Pfizer) and recombinant protein (Novavax). The first two strategies have become well-established, with millions of vaccinated subjects (I got my first jab in August 2020 as a subject in the Moderna Phase III trial). Some concerns have emerged with the recombinant adenovirus vaccines, none with the mRNA vaccines.
Because of technical issues, the Novavax vaccine was late to the table. For some folks, a protein vaccine may not be as scary, and this one uses protein expressed in Fall Army Worm cells infected by an insect virus (no human fetal tissues).
The chief advantage of the Novavax vaccine is that it doesn't require as stringent storage conditions, but storage hasn't proven to be the barrier to vaccination in the industrialized world; that barrier is ignorance/paranoia. At present, there's no vaccine for stupidity. https://www.medpagetoday.com/opinion/second-opinions/99147?xid=nl_secondopinion_2022-06-12&eun=g1700464d0r&fbclid=IwAR1dapcLm5GcEGtl-qRasiDH6Mrt_JdctdWmqNxn6lsXwADZ2nsiXlC4KwU

Comments

Popular posts from this blog

Two sides

Is Joe Biden too old?

My 9/11 memorial